# LYSMD2

## Overview
LYSMD2 is a gene that encodes the protein LysM domain containing 2, which is implicated in immune response and pathogen recognition. The protein is characterized by the presence of a LysM domain, a structural motif known for its ability to bind peptidoglycans, which are integral components of bacterial cell walls. This binding capability positions LYSMD2 as a crucial player in the immune system's ability to detect and respond to bacterial infections. The protein is primarily active in the cytoplasm of human cells, where it may engage in signaling pathways that modulate immune responses, thereby contributing to immune homeostasis and defense against microbial threats. Research has also highlighted LYSMD2's potential role in cancer biology, particularly in melanoma and lung cancer, where it may influence survival outcomes and interact with specific metabolites (Miñoza2022Biomarker; Aftab2023An). Despite its recognized functions, the detailed molecular mechanisms of LYSMD2's involvement in immune and cancer-related pathways remain an active area of investigation.

## Function
LYSMD2 (LysM domain containing 2) encodes a protein that plays a significant role in the immune response and cell wall recognition processes in human cells. The protein contains a LysM domain, which is known for its ability to bind to peptidoglycans, key components of bacterial cell walls. This binding capability suggests that LYSMD2 is involved in pathogen recognition, an essential function in the immune system's ability to identify and respond to bacterial infections.

In healthy human cells, LYSMD2 proteins are primarily active in the cytoplasm, where they may participate in signaling pathways that modulate immune responses. By recognizing and binding to peptidoglycans, LYSMD2 can potentially trigger downstream signaling events that activate immune responses, helping the organism to effectively combat bacterial pathogens. This function underscores the importance of LYSMD2 in maintaining immune homeostasis and protecting the body from infections.

The precise molecular mechanisms by which LYSMD2 influences immune signaling pathways remain an area of active research. However, its role in pathogen recognition and immune modulation highlights its potential significance in both innate and adaptive immune responses, contributing to the organism's overall defense strategy against microbial threats.

## Clinical Significance


## Interactions
LYSMD2, a protein encoded by the human gene LYSMD2, is known to participate in various interactions that may influence cellular processes. In the context of melanoma, high expression of LYSMD2 is associated with better survival outcomes, suggesting a potential role in modulating cancer progression (Miñoza2022Biomarker). The protein is also identified as one of the top 30 significant genes in biomarker discovery for melanoma, indicating its involvement in genetic interactions that could be crucial for disease classification and prognosis (Miñoza2022Biomarker).

In lung cancer research, LYSMD2 has been identified as a potential binding protein for AICAR, an intrinsic purine metabolite. This interaction suggests that LYSMD2 might be involved in the cytotoxic effects of AICAR on EGFR-mutant lung cancer cells, although specific details of this interaction are not fully elucidated (Aftab2023An).

The role of LYSMD2 in these interactions highlights its potential involvement in regulatory pathways and its significance in cancer biology. However, detailed mechanisms of how LYSMD2 interacts with other proteins or nucleic acids remain to be fully explored.


## References


[1. (Miñoza2022Biomarker) Jose Marie Antonio Miñoza, Jonathan Adam Rico, Pia Regina Fatima Zamora, Manny Bacolod, Reinhard Laubenbacher, Gerard G. Dumancas, and Romulo de Castro. Biomarker discovery for meta-classification of melanoma metastatic progression using transfer learning. Genes, 13(12):2303, December 2022. URL: http://dx.doi.org/10.3390/genes13122303, doi:10.3390/genes13122303. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes13122303)

[2. (Aftab2023An) Fareesa Aftab, Alice Rodriguez-Fuguet, Luis Silva, Ikei S. Kobayashi, Jiao Sun, Katerina Politi, Elena Levantini, Wei Zhang, Susumu S. Kobayashi, and Wen Cai Zhang. An intrinsic purine metabolite aicar blocks lung tumour growth by targeting oncoprotein mucin 1. British Journal of Cancer, 128(9):1647–1664, February 2023. URL: http://dx.doi.org/10.1038/s41416-023-02196-z, doi:10.1038/s41416-023-02196-z. This article has 5 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-023-02196-z)